
PhaseV is a Boston-based technology company that leverages advanced causal machine learning and GenAI, augmented by an expansive data lake and real-world data (RWD), to empower biopharma sponsors and CROs with fast, accurate, and efficient clinical development decisions. The company offers a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, helping clients to rapidly design and implement adaptive and Bayesian clinical trials, analyze data for heterogeneous treatment effects, and improve trial planning. With over 30 biopharma and CRO customers and a commitment to transforming clinical development, PhaseV is positioned to bring new treatments to patients more efficiently.

PhaseV is a Boston-based technology company that leverages advanced causal machine learning and GenAI, augmented by an expansive data lake and real-world data (RWD), to empower biopharma sponsors and CROs with fast, accurate, and efficient clinical development decisions. The company offers a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, helping clients to rapidly design and implement adaptive and Bayesian clinical trials, analyze data for heterogeneous treatment effects, and improve trial planning. With over 30 biopharma and CRO customers and a commitment to transforming clinical development, PhaseV is positioned to bring new treatments to patients more efficiently.
Founded: 2023
Headquarters: Cambridge / Boston, MA
Sector: AI/ML for clinical trial optimization (biopharma/CRO)
Customers: 30–45+ biopharma and CRO customers (company claims)
Funding: Series A on 2025-05-13; total funding reported ~$65M
Clinical trial design and operations optimization, subgroup/heterogeneous treatment effect analysis, adaptive and Bayesian trial implementation.
2023
Pharmaceutical Manufacturing
Seed round participation included Viola Ventures
Series A reported as led by Accel and Insight Partners
“Participation from Accel, Insight Partners, Exor Ventures, Viola Ventures, LionBird”
| Company |
|---|